Memphasys Limited (ASX:MEM) specialises in advanced reproductive biotechnology, developing medical devices, diagnostics, and proprietary media for human and animal applications. With flagship technologies like the Felix(TM) and RoXsta(TM) Systems, Memphasys is committed to delivering transformative solutions that enhance fertility outcomes worldwide.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce the successful unblinding and data analysis of its pivotal clinical trial for the Felix(TM) System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce successful completion of the data lock for the pivotal Felix(TM) clinical trial. This marks a critical milestone in ensuring the accuracy and integrity of the trial data.
